Despite the growing global threat of antimicrobial
resistance, many large pharmaceutical companies have reduced or exited
antimicrobial research and development. This trend contrasts with sustained
investment in areas such as oncology and chronic disease therapeutics.

Which factor most strongly explains this withdrawal?

Question

Despite the growing global threat of antimicrobial
resistance, many large pharmaceutical companies have reduced or exited
antimicrobial research and development. This trend contrasts with sustained
investment in areas such as oncology and chronic disease therapeutics.

Which factor most strongly explains this withdrawal?

Accepted Answer

Antimicrobials
typically generate limited long-term revenue relative to development costs,
particularly because they are used short-term and stewardship limits their use

Answer

Pharmaceutical
companies lack the expertise required to develop antimicrobial agents

Answer

The
scientific and technical challenges of antimicrobial discovery exceed those of
other therapeutic areas

Answer

The
incidence of serious infections in high-income countries is too low to justify
investment

Crowdly

Despite the growing global threat of antimicrobial resistance, many large pharm...

Want instant access to all verified answers on learning.monash.edu?